---
title: Current and upcoming treatment approaches to common subtypes of PTCL (PTCL
  NOS, ALCL, TFHs)
date: '2024-02-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38306597/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240203170617&v=2.18.0
source: Blood
description: Treatment of the common nodal peripheral T-cell lymphomas (PTCLs), which
  include PTCL, not otherwise specified (PTCL, NOS), anaplastic large cell lymphomas,
  and T-follicular helper lymphomas, is evolving. These entities are currently treated
  similarly with CHOP or CHOEP for CD30-negative diseases or brentuximab vedotin plus
  CHP for CD30-positive diseases, followed by consolidation with autologous stem cell
  transplant in first remission. Ongoing improvements in PTCL classification, ...
disable_comments: true
---
Treatment of the common nodal peripheral T-cell lymphomas (PTCLs), which include PTCL, not otherwise specified (PTCL, NOS), anaplastic large cell lymphomas, and T-follicular helper lymphomas, is evolving. These entities are currently treated similarly with CHOP or CHOEP for CD30-negative diseases or brentuximab vedotin plus CHP for CD30-positive diseases, followed by consolidation with autologous stem cell transplant in first remission. Ongoing improvements in PTCL classification, ...